RXRX
NASDAQRecursion Pharmaceuticals Inc.
Price$3.31-0.08 (-2.50%)
12:00 PM07:45 PM
News · 26 weeks80-8%
2025-12-142026-06-07
Mix4090d
- Insider21(53%)
- Other10(25%)
- SEC Filings6(15%)
- Leadership2(5%)
- Earnings1(3%)
Latest news
25 items- INSIDERDirector Gibson Christopher converted options into 40,000 shares and sold $144,800 worth of shares (40,000 units at $3.62) as part of a pre-agreed trading plan (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERCEO and President Khan Najat sold $84,459 worth of shares (23,588 units at $3.58) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,175,796 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERDirector Bumpus Namandje sold $15,526 worth of shares (4,386 units at $3.54) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 43,171 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERDirector Borgeson Blake sold $110,400 worth of shares (30,000 units at $3.68) as part of a pre-agreed trading plan, decreasing direct ownership by 0.48% to 6,169,863 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- PRRecursion to Participate in Upcoming Investor ConferencesSalt Lake City, UT, June 02, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced its participation in an upcoming investor conference: Goldman Sachs 47th Annual Global Healthcare Conference — Tuesday, June 9, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com. About RecursionRecursion (NASDAQ:RXRX) is a clinical-stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncolog
- PRRecursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesSalt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 2,991,840 shares of its class A common stock in the aggregate to 33 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the "2024 Plan"). Each award was granted as an inducement material to the employee's commencement of employment with Recursion, or a subsidiary of Recursion, pursuant to Nasdaq Listing Rule 5635(c)(4). Each inducement RSU
- INSIDERDirector Gibson Christopher converted options into 40,000 shares and sold $123,200 worth of shares (40,000 units at $3.08) as part of a pre-agreed trading plan (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERCEO and President Khan Najat covered exercise/tax liability with 62,701 shares, decreasing direct ownership by 3% to 2,199,384 units (SEC Form 4) (for withholding tax)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERChief Scientific Officer Hallett David covered exercise/tax liability with 26,657 shares, decreasing direct ownership by 2% to 1,070,494 units (SEC Form 4) to cover withholding tax4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERDirector Gibson Christopher covered exercise/tax liability with 22,821 shares, decreasing direct ownership by 3% to 883,735 units (SEC Form 4) (for tax liability)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERChief Financial Officer Taylor Ben R covered exercise/tax liability with 25,018 shares, decreasing direct ownership by 2% to 1,107,272 units (SEC Form 4) to cover withholding tax4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- PRAltitude Lab Portfolio Companies Surpass $205 Million in Funding, Marking a New Era for Early-Stage Biotechs in Salt Lake CitySALT LAKE CITY, May 19, 2026 (GLOBE NEWSWIRE) -- Altitude Lab, the platform-first biotech-startup accelerator founded by Recursion (NASDAQ:RXRX), announced today that its portfolio companies have collectively raised more than $205 million in early-stage funding since the program's launch in 2020. The milestone reflects a portfolio of companies advancing into clinical trials, signing deals with global pharma, and commercializing platform technologies reshaping the boundaries of early-stage biotech despite this difficult funding climate. Dr. Joshua Schiffman, CEO/Co-founder of Peel Therapeutics, credits their success to initial support from Altitude Lab, "With Altitude Lab serving as our bi
- SECSEC Form SCHEDULE 13G filed by Recursion Pharmaceuticals Inc.SCHEDULE 13G - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
- PRThe Future of Intoxication Detection May Be in Your VoiceAUSTIN, Texas, May 11, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: The ability to accurately detect drug and alcohol intoxication has long been a persistent challenge across industries, from law enforcement and workplace safety to healthcare and public health management. Traditional methods such as breathalyzers, blood tests and urine screenings are often limited by their invasiveness, delayed results or inability to assess real-time impairment, particularly in cases involving multiple substances. As patterns of substance use evolve and the societal costs of impaired behavior continue to rise, the demand for faster, more scalable and noninvasive diagnostic solutions is becoming
- INSIDERDirector Gibson Christopher converted options into 60,000 shares, sold $134,800 worth of shares (40,000 units at $3.37) as part of a pre-agreed trading plan and gifted 20,000 shares (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- INSIDERDirector Borgeson Blake sold $105,600 worth of shares (30,000 units at $3.52) as part of a pre-agreed trading plan, decreasing direct ownership by 0.48% to 6,199,863 units (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- SECSEC Form 10-Q filed by Recursion Pharmaceuticals Inc.10-Q - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
- SECRecursion Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
- SECSEC Form DEF 14A filed by Recursion Pharmaceuticals Inc.DEF 14A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
- SECSEC Form DEFA14A filed by Recursion Pharmaceuticals Inc.DEFA14A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
- SECRecursion Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - RECURSION PHARMACEUTICALS, INC. (0001601830) (Filer)
- PRRecursion Announces Board TransitionSalt Lake City, UT, April 30, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Chris Gibson, Ph.D., will complete his current term through June 2026 and does not intend to seek re-election to the Company's Board of Directors. "I greatly appreciated Chris's partnership during my transition into the CEO role at Recursion and am pleased that he will remain an advisor to the company moving forward," said Najat Khan, Ph.D., Chief Executive Officer and President of Recursion. "We remain focused on continuity and long-term value creation at Recursion. With a strong foundation and team
- PRRecursion to Report First Quarter 2026 Business Updates and Financial Results on May 6Salt Lake City, UT, April 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2026 financial results on Wednesday, May 6, 2026, before the open of the financial markets. Recursion will host an Earnings Call on May 6, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm BST. The company will broadcast the live stream from Recursion's X, LinkedIn, and YouTube accounts. Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFmikcu6. About RecursionR
- INSIDERDirector Gibson Christopher converted options into 40,000 shares and sold $144,400 worth of shares (40,000 units at $3.61) as part of a pre-agreed trading plan (SEC Form 4)4 - RECURSION PHARMACEUTICALS, INC. (0001601830) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Recursion Pharmaceuticals Inc.SCHEDULE 13G/A - RECURSION PHARMACEUTICALS, INC. (0001601830) (Subject)
RXRX FAQ
7 questionsWhat does Recursion Pharmaceuticals Inc. do?
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. It has four clinical-stage drug candidates focused on rare, monogenic diseases; and 33 additional programs in various stages of preclinical development. Recursion Pharmaceuticals, Inc. has strategic agreements with Bayer; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. The company was founded in 2013 and is...Where does RXRX stock trade?
Recursion Pharmaceuticals Inc. (RXRX) is listed on NASDAQ.What sector and industry is RXRX in?
Recursion Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Recursion Pharmaceuticals Inc. go public?
Recursion Pharmaceuticals Inc. (RXRX) completed its IPO in 2021.What are analysts saying about RXRX?
Recursion Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $1100.00 price target on 2025-12-17.What companies are similar to RXRX?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare RXRX side-by-side with any of them on Quantisnow.How can I track RXRX on Quantisnow?
Quantisnow aggregates Recursion Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RXRX to receive live email and push alerts on every new disclosure.